NasdaqCM:CELCBiotechs
Is Celcuity’s (CELC) New Board Appointment a Turning Point for Its Commercial Strategy?
Celcuity Inc. recently appointed Charles (Chip) R. Romp, a veteran oncology-focused pharmaceutical executive and current CEO of Secura Bio, to its Board of Directors, adding more than 25 years of commercial and sales leadership experience to the company.
Romp’s track record helping build commercial franchises for oncology drugs at Seagen and Genentech adds board-level insight that aligns directly with Celcuity’s focus on bringing targeted cancer therapies to market.
We’ll now look at how...